PTC Therapeutics, Inc.
PTCT
Rang în acțiuni
#3481
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Preț acțiune
$59.28
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$4.95B
Schimbare (1 zi)
-2.80%
Schimbare (1 an)
-10.11%
Țară
US
Tranzacționează PTC Therapeutics, Inc. (PTCT)
Categorie
Healthcare
Marja operațională pentru PTC Therapeutics, Inc. (PTCT)
Marja operațională la October 2026 TTM: 11.52%
Conform celor mai recente rapoarte financiare și prețului acțiunilor PTC Therapeutics, Inc., marja operațională curentă (TTM) este 11.52%. La finalul anului 2023, compania avea o marjă operațională de -37.26%.
Istoricul marjei operaționale pentru PTC Therapeutics, Inc. din 2011 până în 2026
Marja operațională la sfârșitul fiecărui an
| An | Marja Operațională | Schimbă |
|---|---|---|
| 2026 (TTM) | 11.52% | -130.72% |
| 2024 | -37.50% | 0.64% |
| 2023 | -37.26% | -40.81% |
| 2022 | -62.95% | -9.58% |
| 2021 | -69.62% | -38.60% |
| 2020 | -113.39% | 80.56% |
| 2019 | -62.80% | 43.71% |
| 2018 | -43.70% | 32.14% |
| 2017 | -33.07% | -79.29% |
| 2016 | -159.67% | -64.88% |
| 2015 | -454.58% | 5.00% |
| 2014 | -432.93% | 198.74% |
| 2013 | -144.92% | 55.58% |
| 2012 | -93.15% | -401.46% |
| 2011 | 30.90% | 0.00% |
Marja operațională pentru companii similare sau concurente
| Companie | Marja Operațională | Diferență în marja operațională | Țara |
|---|---|---|---|
| 38.59% | -96.65% |
US
|
|
| -149.01% | -112.93% |
US
|
|
| 25.57% | -97.78% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.50% |
NL
|
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.